您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > AL 8810 isopropyl ester
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
AL 8810 isopropyl ester
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
AL 8810 isopropyl ester图片
CAS NO:208114-93-6
规格:98%
分子量:444.6
包装与价格:
包装价格(元)
1mg电议
5mg电议
10mg电议

产品介绍
lipid soluble, esterified prodrug form of AL 8810, a FP receptor antagonist
CAS:208114-93-6
分子式:C27H37FO4
分子量:444.6
纯度:98%
存储:Store at -20°C

Background:

EC50: 430 nM


AL 8810 is a a FP receptor antagonist.


Prostaglandin F receptor (FP), a receptor belonging to the prostaglandin (PG) group of receptors, binds to and mediates the biological actions of Prostaglandin F2α (PGF2α).


In vitro: Previous study found that AL-8810 had weak agonist potency in A7r5 cells and 3T3 fibroblasts. AL-8810 exhibited properties of an apparent competitive antagonist, which was demonstrated by producing parallel dextral shifts of the agonist concentration-response curves and no significant suppression of the maximal agonist-induced response. In addition, AL-8810 could dose-dependently antagonize the response to 100 nM fluprostenol in A7r5 cells, but however, AL-8810 could not significantly inhibit functional responses of DP, TP, EP(2), EP(4), receptor subtypes even at 10 μM concentration [1].


In vivo: In a previous study, the effect of acute intraperitoneal post-treatment with AL-8810 was studied in FP receptor knockout (FP-/-) mice after controlled cortical impact (CCI). Results showed that post-treatment with AL-8810 had no significant effect on cortical lesions, suggesting the irreversible effect of primary CCI injury, but significantly reduced hippocampal swelling. In addition, AL-8810 treatment at a dose of 10 mg/kg could significantly improve NDS after CCI, and in the AL-8810 group, CCI-induced decrease in grip strength was three-fold less [2].


Clinical trial: Up to now, AL 8810 is still in the preclinical development stage.


参考文献:
[1] B.  W. Griffen, P. Klimko, J. Y. Crider, et al. AL-8810: A novel prostaglandin F2α analog with selective antagonist effects at the prostaglandin F2α (FP) receptor. Journal of Pharmacology and Experimental Therapeutics 290(3), 1278-1284 (1999).
[2] Glushakov AV, Robbins SW, Bracy CL, Narumiya S, Doré S.  Prostaglandin F2α FP receptor antagonist improves outcomes after experimental traumatic brain injury. J Neuroinflammation. 2013 Oct 30;10:132. doi: 10.1186/1742-2094-10-132.